Molindone
Clinical data | |
---|---|
Trade names | Moban |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a682238 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Elimination half-life | 1.5 hours |
Excretion | Minor, renal and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C16H24N2O2 |
Molar mass | 276.374 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Molindone |
Articles |
---|
Most recent articles on Molindone |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Molindone at Clinical Trials.gov Clinical Trials on Molindone at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Molindone
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Molindone Discussion groups on Molindone Directions to Hospitals Treating Molindone Risk calculators and risk factors for Molindone
|
Healthcare Provider Resources |
Causes & Risk Factors for Molindone |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Molindone (Moban) is a therapeutic antipsychotic, used in the treatment of schizophrenia.[1] It works by blocking the effects of dopamine in the brain, leading to diminished psychoses. It is rapidly absorbed when taken orally.
It is sometimes described as a typical antipsychotic,[2] and sometimes described as an atypical antipsychotic.[3]
Molindone was discontinued by its sole supplier, Endo Pharmaceuticals, on January 13, 2010. [4]
Adverse effects
The side effect profile of molindone is similar to that of other typical antipsychotics. Unlike most antipsychotics, however, molindone use is associated with weight loss.[3][5]
See also
References
- ↑ "molindone". F.A. Davis Company.
- ↑ Aparasu RR, Jano E, Johnson ML, Chen H (October 2008). "Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients". Am J Geriatr Pharmacother. 6 (4): 198–204. doi:10.1016/j.amjopharm.2008.10.003. PMID 19028375.
- ↑ 3.0 3.1 Bagnall A, Fenton M, Kleijnen J, Lewis R (2007). Bagnall, Anne-Marie, ed. "Molindone for schizophrenia and severe mental illness". Cochrane Database Syst Rev (1): CD002083. doi:10.1002/14651858.CD002083.pub2. PMID 17253473.
- ↑ http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm
- ↑ Allison DB; Mentore JL; Heo M; et al. (1999). "Antipsychotic-induced weight gain: a comprehensive research synthesis". Am J Psychiatry. 156 (11): 1686–96. PMID 10553730. Unknown parameter
|author-separator=
ignored (help) Free full text
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with citations using unsupported parameters
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Articles with changed DrugBank identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Drugboxes which contain changes to verified fields
- Drug
- Morpholines
- Indoles
- Ketones
- Atypical antipsychotics